Advertisement

Low-Dose Radiation Prevents Chemotherapy-Induced Cardiotoxicity

  • Jing Xu
  • Dandan Liu
  • Shengxiang Xiao
  • Xinxin Meng
  • Di Zhao
  • Xin Jiang
  • Xue Jiang
  • Lu Cai
  • Hongyu JiangEmail author
Radiation Biology and Stem Cells (CD Porada and PF Wilson Jr, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Radiation Biology and Stem Cells

Abstract

Purpose of Review

In this review, we will address the cardioprotective effect of low-dose radiation (LDR) on chemotherapeutic agents.

Recent Findings

Cancer has become the most important cause of death in the world, and the morbidity and mortality are gradually increased. The application of anti-tumor drugs is an important therapeutic tool for cancer therapy at present, while its potential cardiotoxicity cannot be ignored. How to prevent and reduce the occurrence of cardiotoxicities needs further exploration.

Summary

LDR induces an adaptive or hormetic response in cells and tissues, showing a tolerance to subsequently high dose of radiation- or chemical-induced damage in vitro and in vivo. LDR may exert its cardioprotective effects through different mechanisms, such as stimulating the proliferation of normal cells during anti-tumor therapy, enhancing anti-tumor immunity, stimulating antioxidative functions in normal tissues, activating DNA damage repair system, and improving metabolic function in normal tissues. Therefore, there may be a potential to apply LDR as an adjunct to myocardial protection for anti-tumor therapy.

Keywords

Low-dose radiation Adaptive response Hormesis Cardiotoxicity Cancer drug 

Notes

Acknowledgments

Works from the authors were supported in part by grants from the Industrial Technology Research and Development (2016C055-2), the International Science and Technology Cooperation Project (20160414004GH), and the National Natural Science Foundation of China (81272471).

Compliance with Ethical Standards

Conflict of Interest

Jing Xu, Dandan Liu, Shengxiang Xiao, Xinxin Meng, Di Zhao, Xin Jiang, Xue Jiang, Lu Cai and Hongyu Jiang declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Yang G, Li W, Jiang H, Liang X, Zhao Y, Yu D, et al. Low-dose radiation may be a novel approach to enhance the effectiveness of cancer therapeutics. Int J Cancer. 2016;139:2157–68.CrossRefPubMedGoogle Scholar
  2. 2.
    Liang X, So YH, Cui J, et al. The low-dose ionizing radiation stimulates cell proliferation via activation of the MAPK/ERK pathway in rat cultured mesenchymal stem cells. J Radiat Res. 2011;52:380–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Feinendegen LE. Evidence for beneficial low level radiation effects and radiation hormesis. Br J Radiol. 2005;78:3–7.CrossRefPubMedGoogle Scholar
  4. 4.
    • Zhou L, Zhang X, Li H, et al. Validating the pivotal role of the immune system in low-dose radiation-induced tumor inhibition in Lewis lung cancer-bearing mice. Cancer Med. 2018;7(4):1338–48. Demonstrated that immune enhancement played a key role in LDR-induced tumor inhibition. These findings emphasized the importance of the immune response in tumor radiotherapy and may help promote the application of LDR as a novel approach in clinical practice. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jiang H, Xu Y, Li W, Ma K, Cai L, Wang G. Low-dose radiation does not induce proliferation in tumor cells in vitro and in vivo. Radiat Res. 2008;170(4):477–87.CrossRefPubMedGoogle Scholar
  6. 6.
    Olivieri G, Bodycote J, Wolff S. Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science. 1984;223:594–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Wang GJ, Cai L. Induction of cell-proliferation hormesis and cell-survival adaptive response in mouse hematopoietic cells by whole-body low-dose radiation. Toxicol Sci. 2000;53:369–76.CrossRefPubMedGoogle Scholar
  8. 8.
    Cai L. Research of the adaptive response induced by low-dose radiation: where have we been and where should we go. Hum Exp Toxicol. 1999;18:419–25.CrossRefPubMedGoogle Scholar
  9. 9.
    Cheda A, Wrembel-Wargocka J, Lisiak E, Nowosielska EM, Marciniak M, Janiak MK. Single low doses of X rays inhibit the development of experimental tumor metastases and trigger the activities of NK cells in mice. Radiat Res. 2004;161:335–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Yu HS, Song AQ, Liu N, et al. Effects of low dose pre-irradiation on hepatic damage and genetic material damage caused by cyclophosphamide. Eur Rev Med Pharmacol Sci. 2014;18(24):3889–97.PubMedGoogle Scholar
  11. 11.
    Bevelacqua JJ, Mortazavi SMJ. Alzheimer‘s disease: possible mechanisms behind neurohormesis induced by exposure to low doses of ionizing radiation. J Biomed Phys Eng. 2018;8(2):153–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Betlazar C, Middleton RJ, Banati RB, et al. The impact of high and low dose ionising radiation on the central nervous system. Redox Biol. 2016;9:144–56.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Truong K, Bradley S, Baginski B, Wilson JR, Medlin D, Zheng L, et al. The effect of well-characterized, very low-dose x-ray radiation on fibroblasts. PLoS One. 2018;13(1):e0190330.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    • Yang G, Yu D, Li W, et al. Distinct biological effects of low-dose radiation on normal and cancerous human lung cells are mediated by ATM signaling. Oncotarget. 2016;7(44):71856–72. Low-dose radiation (LDR) induces hormesis and adaptive response in normal cells but not in cancer cells maybe mediated by ATM signalling. PubMedPubMedCentralGoogle Scholar
  15. 15.
    Walaszczyk A, Szołtysek K, Jelonek K, Polańska J, Dörr W, Haagen J, et al. Heart irradiation reduces microvascular density and accumulation of HSPA1 in mice. Strahlenther Onkol. 2018;194(3):235–42.CrossRefPubMedGoogle Scholar
  16. 16.
    Steven E. Lipshultz, Melissa B, et al. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. Paediatr Drugs 2014;16(5):373–89.Google Scholar
  17. 17.
    • McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75. The cardiotoxic mechanisms of anthracyclines may involve the dual pathways of reactive oxidation species and topoisomerase 2-beta and a final common pathway of calcium overload, lipid peroxidation, and mitochondrial dysfunction. There is no universally accepted definition of anthracycline cardiotoxicity, and thus its incidence varies according to how it is defined. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.CrossRefPubMedGoogle Scholar
  19. 19.
    Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman’s pharmacological basis of therapeutics. New York: McGraw-Hill; 2010.Google Scholar
  20. 20.
    Ferrans VJ, Clark JR, Zhang J, et al. Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia. 1997;39:928–37.PubMedGoogle Scholar
  21. 21.
    Hrdina R, Gersl V, Klimtova I, et al. Anthracycline-induced cardiotoxicity. Acta Med (Hradec Kralove). 2000;43:75–82.Google Scholar
  22. 22.
    Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2006;5:791–809.CrossRefPubMedGoogle Scholar
  23. 23.
    Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561–78.CrossRefPubMedGoogle Scholar
  24. 24.
    Bickford CL, Yeh ET. Cardiotoxicity of other anti-cancer treatment. In: Ewer MS, Yeh ET, editors. Cancer and the heart. 2nd ed. Shelton: People's Medical Publishing House - USA, Ltd; 2013. p. 69–82.Google Scholar
  25. 25.
    Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern Med. 2005;44:89–90.CrossRefPubMedGoogle Scholar
  26. 26.
    O'Connell TX, Berenbaum MC. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res. 1974;34:1586–91.PubMedGoogle Scholar
  27. 27.
    Kim H, Chung W-B, Cho KI, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasoun. 2018;26(1):1–25.CrossRefGoogle Scholar
  28. 28.
    Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685–96.CrossRefPubMedGoogle Scholar
  29. 29.
    Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50(2):254–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother. 2012;61:215–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31(6):459–67.CrossRefPubMedGoogle Scholar
  32. 32.
    Jain D, Russell RR, Schwartz RG, Panjrath GS, Aronow W. Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions. Curr Cardiol Rep. 2017;19:36.CrossRefPubMedGoogle Scholar
  33. 33.
    Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014;64:938–45.CrossRefPubMedGoogle Scholar
  34. 34.
    • Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735. Demonstrate that the induction of death receptors in cardiomyocytes is likely a critical mechanism by which doxorubicin causes cardiotoxicity. CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154–71.CrossRefPubMedGoogle Scholar
  36. 36.
    Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Halliwell B. Oxidants and human disease: some new concepts. FASEB J. 1987;1(5):358–64.CrossRefPubMedGoogle Scholar
  38. 38.
    Sies H. Oxidative stress, oxidants and antioxidants. London: Academic Press; 1991.Google Scholar
  39. 39.
    Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.  https://doi.org/10.1016/j.biocel.2006.07.001.CrossRefGoogle Scholar
  40. 40.
    Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 1977;197:165–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem. 1986;261:3068–74.PubMedGoogle Scholar
  42. 42.
    Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol. 2002;34:1595–607.CrossRefPubMedGoogle Scholar
  43. 43.
    Li K, Sung RY, Huang WZ, et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation. 2006;113:2211–20.CrossRefPubMedGoogle Scholar
  44. 44.
    Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radicaldependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47:219–31.CrossRefPubMedGoogle Scholar
  45. 45.
    Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Oxford: Oxford University Press; 2007.Google Scholar
  46. 46.
    Thomas CE, Aust SD. Release of iron from ferritin by cardiotoxic anthracycline antibiotics. Arch Biochem Biophys. 1986;248:684–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004;18:664–75.CrossRefPubMedGoogle Scholar
  48. 48.
    Hershko C, Link G, Tzahor M, et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med. 1993;122:245–51.PubMedGoogle Scholar
  49. 49.
    Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of ironanthracycline interaction. J Lab Clin Med. 1996;127:272–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Stowe DF, Camara AKS. Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function. Antioxid Redox Signal. 2009;11:1373–96.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Camara A, Lesnefsky E, Stowe D. Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal. 2010;13:279–347.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Koopman WJ, Nijtmans LG, Dieteren CE, et al. Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation. Antioxid Redox Signal. 2010;12:1431–70.CrossRefGoogle Scholar
  53. 53.
    Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys. 1999;368:421–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23:15–25.CrossRefPubMedGoogle Scholar
  55. 55.
    Hulbert AJ, Pamplona R, Buffenstein R, Buttemer WA. Life and death: metabolic rate, membrane composition, and life span of animals. Physiol Rev. 2007;87:1175–213.CrossRefPubMedGoogle Scholar
  56. 56.
    Tamura M, Matsui H, Kaneko T, Hyodo I. Alcohol is an oxidative stressor for gastric epithelial cell: detection of superoxide in living cells. J Clin Biochem Nutr. 2013;53(2):75–80.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Childs AC, Phaneuf SL, Dirks AJ, et al. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 2002;62:4592–8.PubMedGoogle Scholar
  58. 58.
    Granados-Principal S, El-Azem N, Pamplona R, et al. Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. Biochem Pharmacol. 2014;90:25–33.CrossRefPubMedGoogle Scholar
  59. 59.
    Chua CC, Liu X, Gao J, Hamdy RC, Chua BHL. Multiple actions of pifithrin-alpha on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells. Am J Physiol Heart Circ Physiol. 2006;290(6):H2606–13.CrossRefPubMedGoogle Scholar
  60. 60.
    Wu W, Lee WL, Wu YY, Chen D, Liu TJ, Jang A, et al. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem. 2000;275(51):40113–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83(5):516–22.CrossRefPubMedGoogle Scholar
  62. 62.
    Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther. 2001;298(2):461–8.PubMedGoogle Scholar
  63. 63.
    Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM. Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem. 1990;35(2–3):247–57.CrossRefPubMedGoogle Scholar
  64. 64.
    Demant EJ. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem Pharmacol. 1991;41(4):543–52.CrossRefPubMedGoogle Scholar
  65. 65.
    Kang YJ, Zhou Z-X, Wang G-W, Buridi A, Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem. 2000;275(18):13690–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Huang J, Yang J, Maity B, Mayuzumi D, Fisher RA. Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res. 2011;71:6310–9.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Premkumar K, Shankar BS. Involvement of MAPK signalling in radioadaptive response in BALB/c mice exposed to low dose ionizing radiation. Int J Radiat Biol. 2016;92:249–62.CrossRefPubMedGoogle Scholar
  68. 68.
    Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48:749–62.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Florentin A, Arama E. Caspase levels and execution efficiencies determine the apoptotic potential of the cell. J Cell Biol. 2012;196:513–27.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Choi HJ, Kang KS, Fukui M, Zhu BT. Critical role of the JNK-p53-GADD45alpha apoptotic cascade in mediating oxidative cytotoxicity in hippocampal neurons. Br J Pharmacol. 2011;162:175–92.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Qin Q, Liao G, Baudry M, Bi X. Cholesterol perturbation in mice results in p53 degradation and axonal pathology through p38 MAPK and Mdm2 activation. PLoS One. 2010;5:e9999.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Banu SK, Stanley JA, Lee J, Stephen SD, Arosh JA, Hoyer PB, et al. Hexavalent chromium-induced apoptosis of granulosa cells involves selective sub-cellular translocation of Bcl-2 members, ERK1/2 and p53. Toxicol Appl Pharmacol. 2011;251:253–66.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Sun J, Sun G, Meng X, Wang H, Luo Y, Qin M, et al. Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. PLoS One. 2013;8(5):e64526.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, et al. Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J. 2005;389:527–39.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Shi J, Abdelwahid E, Wei L. Apoptosis in anthracycline cardiomyopathy. Curr Pediatr Rev. 2011;7(4):329–36.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Li H, Gu H, Sun B. Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol. 2007;114:159–65.CrossRefPubMedGoogle Scholar
  77. 77.
    Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation. 2004;110:2869–74.CrossRefPubMedGoogle Scholar
  78. 78.
    Nitobe J, Yamaguchi S, Okuyama M, et al. Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes. Cardiovasc Res. 2003;57:119–28.CrossRefPubMedGoogle Scholar
  79. 79.
    Mercier I, Vuolo M, Madan R, Xue X, Levalley AJ, Ashton AW, et al. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ. 2005;12:682–6.CrossRefGoogle Scholar
  80. 80.
    An J, Li P, Li J, Dietz R, Donath S. ARC is a critical cardiomyocyte survival switch in doxorubicin cardiotoxicity. J Mol Med. 2009;87:401–10.CrossRefPubMedGoogle Scholar
  81. 81.
    You W, Zhou T, Gao Y, et al. Ophiopogonin D maintains Ca2+ homeostasis in rat cardiomyocytes in vitro by upregulating CYP2J3/EETs and suppressing ER stress. Acta Pharmacol Sin. 2016;37(3):368–81.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Wu J, Guo W, Kan J-T, et al. Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity. Cell Death Dis. 2016;7(8):e2339.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Asensio-López MC, Soler F, Pascual-Figal D, Fernández-Belda F, Lax A. Doxorubicin-induced oxidative stress: the protective effect of nicorandil on HL-1 cardiomyocytes. PLoS One. 2017;12(2):e0172803.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Xiong C, Wu Y, Yu Z, et al. Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment. Oncol Lett. 2018;15(4):5721–9.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Xiong C, Li JX, Guo HC, Zhang LN, Guo W, Meng J, et al. The H1-H2 domain of the α1 isoform of Na+-K+-ATPase is involved in ouabain toxicity in rat ventricular myocytes. Toxicol Appl Pharmacol. 2012;262(1):32–42.Google Scholar
  86. 86.
    Kryshtal DO, Gryshchenko O, Gomez-Hurtado N, et al. Impaired calcium-calmodulin-dependent inactivation of Cav1.2 contributes to loss of sarcoplasmic reticulum calcium release refractoriness in mice lacking calsequestrin 2. J Mol Cell Cardiol. 2015;82:75–83.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    • Koleini N, Kardami E. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget. 2017;8(28):46663–80. Dox leads to an over-activation of autophagy initiation while at the same time preventing autophagy completion due to deleterious effects on lysosomes. The resulting accumulation of un-degraded cargo which promotes ROS overproduction would be expected to be toxic to the cells, contributing to cell death. CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Wang X, Wang XL, Chen HL, Wu D, Chen JX, Wang XX, et al. Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem Pharmacol. 2014;88:334–50.CrossRefPubMedGoogle Scholar
  89. 89.
    Lee BS, Oh J, Kang SK, Park S, Lee SH, Choi D, et al. Insulin protects cardiac myocytes from doxorubicin toxicity by Sp1-mediated transactivation of survivin. PLoS One. 2015;10:e0135438.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Chahine N, Makhlouf H, Duca L, Martiny L, Chahine R. Cardioprotective effect of saffron extracts against acute doxorubicin toxicity in isolated rabbit hearts submitted to ischemia-reperfusion injury. Z Naturforsch C. 2014;69:459–70.CrossRefPubMedGoogle Scholar
  91. 91.
    Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation. 2009;119:99–106.CrossRefPubMedGoogle Scholar
  92. 92.
    Singla DK. Akt-mTOR pathway inhibits apoptosis and fibrosis in doxorubicin-induced cardiotoxicity following embryonic stem cell transplantation. Cell Transplant. 2015;24:1031–42.CrossRefPubMedGoogle Scholar
  93. 93.
    Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003;35:851–9.CrossRefPubMedGoogle Scholar
  94. 94.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81.CrossRefPubMedGoogle Scholar
  95. 95.
    Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signalling and cytoskeletal remodelling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41:228–35.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Csapo M, Lazar L. Chemotherapy-induced cardiotoxicity: pathophysiology and prevention. Clujul Med. 2014;87(3):135–42.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Hazelton WD, Moolgavkar SH, Curtis SB, et al. Biologically based analysis of lung cancer incidence in a large Canadian occupational cohort with low-dose ionizing radiation exposure, and comparison with Japanese atomic bomb survivors. J Toxic Environ Health A. 2006;69:1013–38.CrossRefGoogle Scholar
  98. 98.
    Zielinski JM, Garner MJ, Band PR, et al. Health outcomes of low-dose ionizing radiation exposure among medical workers: a cohort study of the Canadian national dose registry of radiation workers. Int J Occup Med Environ Health. 2009;22:149–56.PubMedGoogle Scholar
  99. 99.
    Zablotska LB, Bazyka D, Lubin JH, Gudzenko N, Little MP, Hatch M, et al. Radiation and the risk of chronic lymphocytic and other leukemias among chornobyl cleanup workers. Environ Health Perspect. 2013;121:59–65.CrossRefPubMedGoogle Scholar
  100. 100.
    Schubauer-Berigan MK, Daniels RD, Bertke SJ, Tseng CY, Richardson DB. Cancer mortality through 2005 among a pooled cohort of U.S. nuclear workers exposed to external ionizing radiation. Radiat Res. 2015;183:620–31.CrossRefPubMedGoogle Scholar
  101. 101.
    Mifune M, Sobue T, Arimoto H, Komoto Y, Kondo S, Tanooka H. Cancer mortality survey in a spa area (Misasa, Japan) with a high radon background. Jpn J Cancer Res. 1992;83:1–5.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Wei LX, Zha YR, Tao ZF, et al. Epidemiological investigation of radiological effects in high background radiation areas of Yangjiang, China. J Radiat Res. 1990;31:119–36.CrossRefPubMedGoogle Scholar
  103. 103.
    Lehrer S, Rosenzweig KE. Lung cancer hormesis in high impact states where nuclear testing occurred. Clin Lung Cancer. 2015;16:152–5.CrossRefPubMedGoogle Scholar
  104. 104.
    Dobrzynski L, Fornalski KW, Feinendegen LE. Cancer mortality among people living in areas with various levels of natural background radiation. Dose-Response. 2015;13:1559325815592391.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Chen SL, Cai L, Meng QY, et al. Low-dose whole-body irradiation (LD-WBI) changes protein expression of mouse thymocytes: effect of a LD-WBI-enhanced protein RIP10 on cell proliferation and spontaneous or radiation-induced thymocyte apoptosis. Toxicol Sci. 2000;55:97–106.CrossRefPubMedGoogle Scholar
  106. 106.
    Hyun SJ, Yoon MY, Kim TH, et al. Enhancement of mitogen-stimulated proliferation of low dose radiation-adapted mouse splenocytes. Anticancer Res. 1997;17:225–9.PubMedGoogle Scholar
  107. 107.
    Kim CS, Kim JK, Nam SY, et al. Low-dose radiation stimulates the proliferation of normal human lung fibroblasts via a transient activation of Raf and Akt. Mol Cells. 2007;24:424–30.PubMedGoogle Scholar
  108. 108.
    Kim CS, Kim JM, Nam SY, et al. Low-dose of ionizing radiation enhances cell proliferation via transient ERK1/2 and p38 activation in normal human lung fibroblasts. J Radiat Res. 2007;48:407–15.CrossRefPubMedGoogle Scholar
  109. 109.
    Suzuki K, Kodama S, Watanabe M. Extremely low-dose ionizing radiation causes activation of mitogen-activated protein kinase pathway and enhances proliferation of normal human diploid cells. Cancer Res. 2001;61:5396–401.PubMedGoogle Scholar
  110. 110.
    Rithidech KN, Scott BR. Evidence for radiation hormesis after in vitro exposure of human lymphocytes to low doses of ionizing radiation. Dose-Response. 2008;6:252–71.CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Anderson RE, Warner NL. Ionizing radiation and the immune response. Adv Immunol. 1976;24:215–335.CrossRefPubMedGoogle Scholar
  112. 112.
    Yang G, Kong Q, Wang G, Jin H, Zhou L, Yu D, et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm. 2014;29:428–34.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Ibuki Y, Goto R. Contribution of inflammatory cytokine release to activation of resident peritoneal macrophages after in vivo low-dose gamma-irradiation. J Radiat Res. 1999;40:253–62.CrossRefPubMedGoogle Scholar
  114. 114.
    Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589–602.CrossRefPubMedGoogle Scholar
  115. 115.
    Liu SZ, Xu S, Zhang YC, Zhao Y. Signal transduction in lymphocytes after low dose radiation. Chin Med J. 1994;107:431–6.PubMedGoogle Scholar
  116. 116.
    Ishii K, Yamaoka K, Hosoi Y, et al. Enhanced mitogen-induced proliferation of rat splenocytes by low-dose whole-body X-irradiation. Physiol Chem Phys Med NMR. 1995;27:17–23.PubMedGoogle Scholar
  117. 117.
    Liu SZ, Han ZB, Liu WH. Changes in lymphocyte reactivity to modulatory factors following low dose ionizing radiation. Biomed Environ Sci. 1994;7:130–5.PubMedGoogle Scholar
  118. 118.
    Sambani C, Thomou H, Kitsiou P. Stimulatory effect of low dose X-irradiation on the expression of the human T lymphocyte CD2 surface antigen. Int J Radiat Biol. 1996;70:711–7.CrossRefPubMedGoogle Scholar
  119. 119.
    Liu SZ, Jin SZ, Liu XD, Sun YM. Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes. BMC Immunol. 2001;2:8.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Safwat A. The role of low-dose total body irradiation in treatment of non-Hodgkin’s lymphoma: a new look at an old method. Radiother Oncol. 2000;56:1–8.CrossRefPubMedGoogle Scholar
  121. 121.
    Liu R, Xiong S, Zhang L, Chu Y. Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells. Cell Mol Immunol. 2010;7:157–62.CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Wang B, Li B, Dai Z, Ren S, Bai M, Wang Z, et al. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4+CD25+ Treg cells. Int J Biochem Cell Biol. 2014;55:98–108.CrossRefPubMedGoogle Scholar
  123. 123.
    Kojima S, Nakayama K, Ishida H. Low dose gamma-rays activate immune functions via induction of glutathione and delay tumor growth. J Radiat Res. 2004;45:33–9.CrossRefPubMedGoogle Scholar
  124. 124.
    Large M, Hehlgans S, Reichert S, Gaipl US, Fournier C, Rödel C, et al. Study of the anti-inflammatory effects of low-dose radiation : the contribution of biphasic regulation of the antioxidative system in endothelial cells. Strahlenther Onkol. 2015;191:742–9.CrossRefPubMedGoogle Scholar
  125. 125.
    Wolff S, Afzal V, Wiencke JK, Olivieri G, Michaeli A. Human lymphocytes exposed to low doses of ionizing radiations become refractory to high doses of radiation as well as to chemical mutagens that induce double-strand breaks in DNA. Int J Radiat Biol. 1988;53:39–47.CrossRefGoogle Scholar
  126. 126.
    Yamaoka K, Kojima S, Takahashi M, Nomura T, Iriyama K. Change of glutathione peroxidase synthesis along with that of superoxide dismutase synthesis in mice spleens after low-dose X-ray irradiation. Biochim Biophys Acta. 1998;1381:265–70.CrossRefPubMedGoogle Scholar
  127. 127.
    Gade S, Gandhi NM. Baicalein inhibits MCF-7 cell proliferation in vitro, induces radiosensitivity, and inhibits hypoxia inducible factor. J Environ Pathol Toxicol Oncol. 2015;34:299–308.CrossRefPubMedGoogle Scholar
  128. 128.
    Lall R, Ganapathy S, Yang M, Xiao S, Xu T, Su H, et al. Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response. Cell Death Differ. 2014;21:836–44.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Sharma NK, Sharma R, Mathur D, et al. Role of ionizing radiation in neurodegenerative diseases. Front Aging Neurosci. 2018;10:134.CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Shimura N, Kojima S. The lowest radiation dose having molecular changes in the living body. Dose-Response. 2018;16(2):1559325818777326.CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Dias JV, Gloaguen C, Kereselidze D, et al. Gamma low-dose-rate ionizing radiation stimulates adaptive functional and molecular response in human aortic endothelial cells in a threshold-, dose-, and dose rate–dependent manner. Dose-Response. 2018;16(1):1559325818755238.Google Scholar
  132. 132.
    Zhao Y, Kong C, Chen X, Wang Z, Wan Z, Jia L, et al. Repetitive exposure to low-dose X-irradiation attenuates testicular apoptosis in type 2 diabetic rats, likely via Akt-mediated Nrf2 activation. Mol Cell Endocrinol. 2016;422:203–10.CrossRefPubMedGoogle Scholar
  133. 133.
    •• Jiang X, Hong Y, Zhao D, et al. Low dose radiation prevents doxorubicin-induced cardiotoxicity. Oncotarget. 2018;9(1):332–45. Suggest that LDR could induce adaptation of the heart to DOX-induced toxicity. Cardiac protection by LDR may attribute to attenuate DOX-induced cell death via suppressing mitochondrial-dependent oxidative stress and apoptosis signaling. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jing Xu
    • 1
  • Dandan Liu
    • 1
  • Shengxiang Xiao
    • 2
  • Xinxin Meng
    • 1
  • Di Zhao
    • 1
  • Xin Jiang
    • 1
  • Xue Jiang
    • 1
  • Lu Cai
    • 3
  • Hongyu Jiang
    • 1
    Email author
  1. 1.Department of Health Examination CenterThe First Hospital of Jilin UniversityChangchunChina
  2. 2.Department of EmergencyThe First Hospital of Jilin UniversityChangchunChina
  3. 3.Pediatric Research Institute, Departments of Pediatrics, Radiation Oncology, Pharmacology and ToxicologyThe University of LouisvilleLouisvilleUSA

Personalised recommendations